openPR Logo
Press release

Ankylosing Spondylitis Therapeutics Pipeline Analysis, 2017 by P&S Market Research

06-19-2017 01:00 PM CET | Health & Medicine

Press release from: P&S Market Research - Pharmaceuticals

Ankylosing Spondylitis Therapeutics Pipeline Analysis, 2017

Ankylosing spondylitis is an idiopathic disease, associated with HLA-B27, IL23R and ERAP1 genes. Usually, fewer people get affected with ankylosing spondylitis irrespective of activation of genes. Blood test, X-ray test, Magnetic Resonance Imaging (MRI) and physical investigations are some of the ways to effectively diagnose the disease. The disease begins with the inflammation in joints in the vertebrae and pelvic bones and spine. The environmental factors are believed to be the most important risk factor for increasing the incidence of the disease. The primary symptoms include back pain and stiffness.

Explore Report at: https://www.psmarketresearch.com/market-analysis/ankylosing-spondylitis-therapeutics-pipeline-analysis

Considerable growth in therapeutic pipeline of ankylosing spondylitis is attributed to the increase in prevalence of the disease among teens as well as young adult patients. Researchers have not been able to identify the actual cause of the disease. Novel anti-inflammatory agents and pain killers are being developed that are primarily responsible for the growth of therapeutics pipeline for ankylosing spondylitis.

In June 2015, UniQuest Pty Ltd signed a collaborative agreement with Janssen Cilag Pty Limited for development and commercialization of small molecule modulators of a biological target identified by the University of Queensland, as an important factor for the treatment of ankylosing spondylitis, and potentially psoriasis and inflammatory bowel disease. In December 2016, Janssen Biotech, Inc. confirmed the submission of two Supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) seeking approval of SIMPONI ARIA (golimumab) for the treatment of patients with psoriatic arthritis as well as ankylosing spondylitis. SIMPONI ARIA is fully humanised anti-tumour necrosis factor alpha therapy.

Request for table of Content at: https://www.psmarketresearch.com/market-analysis/ankylosing-spondylitis-therapeutics-pipeline-analysis/toc-sample

Some of the companies having a pipeline of ankylosing spondylitis therapeutics include, AbbVie Inc., Sanofi SA, Centocor Inc., Regeneron Pharmaceuticals Inc., F. Hoffmann-La Roche AG, Janssen Research & Development, LLC, Novartis AG, Amgen plc, Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Merck Sharp & Dohme Corp., Galapagos NV, Celgene Corporation, Shanghai Pharmaceuticals Holding Co., Ltd, Innovent Biologics (Suzhou) Co. Ltd., Pfizer Inc., UCB Pharma SA, Eli Lilly and Company, Eisai Co., Ltd., Korea Otsuka Pharmaceutical Co., Ltd., Inflexxion Inc. and Johnson & Johnson Pvt. Ltd.

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
Kundan
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Ankylosing Spondylitis Therapeutics Pipeline Analysis, 2017 by P&S Market Research here

News-ID: 585476 • Views:

More Releases from P&S Market Research - Pharmaceuticals

Psoriasis Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments
Psoriasis Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Paten …
The study analyzed that the psoriasis therapeutics pipeline comprises approximately 150 drug candidates in different stages of development. Psoriasis is a chronic inflammatory disorder that causes red patches covered with white scales on the skin. It is characterized when a person’s immune system sends defective signals which results in skin cells to grow rapidly. The body does not shed these excess skin cells and pile up on the surface of
Diabetic Foot Ulcer Therapeutics Pipeline Projects Immense Growth Ahead
Diabetic Foot Ulcer Therapeutics Pipeline Projects Immense Growth Ahead
The study analysed that the diabetic foot ulcer pipeline comprises of approximately 27 drug candidates in different stages of development. Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/diabetic-foot-ulcers-therapeutics-pipeline-analysis Diabetic foot ulcer is a serious complication of diabetes and can be defined as the ulceration in foot along with neuropathy or peripheral artery disease of the lower limb in diabetic patients. Diabetic foot ulcer is categorized into two types namely; neuropathic foot where
Technological Advancements at Cellular and Molecular Level Strengthening the IgA Nephropathy Pipeline
Technological Advancements at Cellular and Molecular Level Strengthening the IgA …
The pipeline involves drug candidates that are being developed using specific targets such as a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BlyS). More than three drug candidates are being developed using subcutaneous route of administration. Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/iga-nephropathy-pipeline-analysis The study analyzed that the IgA nephropathy therapeutics pipeline comprises of 24 drug candidates in different stages of development. The report also includes epidemiology forecast for IgA Nephropathy for the
Idiopathic Pulmonary Fibrosis (IPF) Therapeutics Pipeline Analysis, 2017
Idiopathic Pulmonary Fibrosis (IPF) Therapeutics Pipeline Analysis, 2017
The study analyzed that the IPF pipeline comprised of 104 drug candidates, of which 19 drugs are in the Phase II stage of development. The lack of complete cure for IPF fuels the extensive research and development for the IPF therapeutic. There are various drugs that are being developed as novel and promising therapeutics for the treatment of IPF. Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/idiopathic-pulmonary-fibrosis-therapeutics-market As per the findings of research, it

All 5 Releases


More Releases for Ankylosing

Ankylosing Spondylitis Medication Market Size And Global Industry Forecast 2034
"As of 2024, the global ankylosing spondylitis (AS) medication market is valued at approximately $5 billion, driven by an increasing prevalence of the condition and a growing awareness of treatment options. The market is projected to reach roughly $9 billion by 2034, reflecting a robust growth trajectory over the next decade. The anticipated Compound Annual Growth Rate (CAGR) for the forecast period from 2025 to 2034 is estimated at around
Ankylosing Spondylitis Market Surges With The Growing Geriatric Population World …
The Ankylosing Spondylitis Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Current Ankylosing Spondylitis Market Size and Its Estimated Growth Rate? The Ankylosing Spondylitis Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034.
Ankylosing Spondylitis Uncovered: Market Dynamics and Future Projections
𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭: https://www.alliedmarketresearch.com/request-sample/2638 Introduction: The global ankylosing spondylitis market has been on a steady rise, reflecting the growing awareness and prevalence of this inflammatory condition. With a remarkable market size of $5,140.94 million in 2020, the projections indicate a substantial leap to $8,110.59 million by 2030. Ankylosing spondylitis, often misunderstood, is a complex disorder that affects the spine's flexibility and posture, potentially leading to severe complications if not managed effectively. Unveiling Ankylosing
Ankylosing Spondylitis Treatment Market to Witness Astonishing Growth by 2029
This Ankylosing Spondylitis Treatment Market research report focuses more on a number of distinctive as well as foremost market sectors. It further focuses market segmentation. Industry-specific interviews are carried out with market players to foresee future business growth. Various facets of the industry are also depicted here under each industry sector. Future development visions and a wide range of subjects are covered in this Ankylosing Spondylitis Treatment Market study report.
Ankylosing Spondylitis Market Overview With Detailed Analysis 2022-2028
According to Precision Business Insights (PBI), the latest report, ankylosing spondylitis market is expected to be valued at USD 5,460.5 million in 2022 which is expected to grow at a CAGR of 4.8% over 2022-2028. The primary factors that drive the market are the presence of biosimilars, usage of novel products, and increasing prevalence of ankylosing spondylitis. View the detailed report description here - https://precisionbusinessinsights.com/market-reports/ankylosing-spondylitis-market/ Retail Pharmacy to Dominate the
Ankylosing Spondylitis Market Challenges and Investment Opportunities by 2027
Allied Market Research published a report, titled, “Ankylosing Spondylitis Market: Global Opportunity Analysis and Industry Forecast 2020–2027.” According to the report, the global Ankylosing Spondylitis industry garnered $XX billion in 2019, and is expected to generate $xx billion by 2027, witnessing a CAGR of xx% from 2020 to 2027. Click Here To Access Sample Report https://www.alliedmarketresearch.com/request-sample/10631 Major players analyzed include AbbVie Inc., Janssen Pharmaceuticals Inc., Pfizer Inc., Sandoz International GmbH, Amgen